Institutional members access full text with Ovid®

Share this article on:

Topical Ranibizumab as a Treatment of Corneal Neovascularization

Ferrari, Giulio MD; Dastjerdi, Mohammad H. MD; Okanobo, Andre MD; Cheng, Sheng-Fu MD; Amparo, Francisco MD; Nallasamy, Nambi; Dana, Reza MD, MSc, MPH

doi: 10.1097/ICO.0b013e3182775f8d
Clinical Science

Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).

Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.

Results: Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.

Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

Supplemental Digital Content is Available in the Text.

*G.B. Bietti Eye Foundation-IRCCS, Rome, Italy

Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA.

Reprints: Giulio Ferrari, Schepens Eye Research Institute, Harvard Medical School, 20 Staniford St, Boston, MA 02114 (e-mail:

G. Ferrari has received a grant from the Bietti Eye Foundation, IRCCS, Rome, Italy; R. Dana received financial support from Genentech, Inc, South San Francisco, CA and NIH EY-019098. The other authors have no financial or conflicts of interest to disclose.

G. Ferrari and M.H. Dastjerdi contributed equally to this work.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (

Received August 16, 2012

Accepted October 02, 2012

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.